Metformin Is Associated With a Lower Risk of Atrial Fibrillation and Ventricular Arrhythmias Compared With Sulfonylureas
Why the study?
Studies investigating the risk of atrial and ventricular arrhythmias in diabetic patients taking different oral diabetes medications were sparse.
Does metformin monotherapy reduce the risk of arrhythmias in patients with type 2 diabetes compared with other oral diabetes medications?
Population
Patients on different oral diabetes medications from IBM MarketScan Medicare Supplemental Database
Comparison
Different oral diabetes medications including metformin, sulfonylureas, DPP4 inhibitors, or thiazolidinediones
Design
Propensity score-matched retrospective database study
Authors
Discussion
Loading...
Member takes
Implication
Metformin was associated with lower arrhythmia risk in type 2 diabetes; leaves open causality and requires prospective trials before practice change.
Structured PICO
Does metformin monotherapy reduce the risk of arrhythmias in patients with type 2 diabetes compared with other oral diabetes medications?
P
Population
Patients with type 2 diabetes on oral diabetes medications from the IBM MarketScan Medicare Supplemental Database
I
Intervention
Metformin monotherapy
C
Comparator
Monotherapy with sulfonylureas, dipeptidyl peptidase 4 (DPP4) inhibitors, or thiazolidinediones
O
Outcome
Risk of atrial arrhythmias (including atrial fibrillation), ventricular arrhythmias, and bradycardiahard clinical
Metformin monotherapy is associated with a lower risk of atrial and ventricular arrhythmias compared to sulfonylureas, DPP4 inhibitors, and thiazolidinediones in patients with type 2 diabetes.
Cite This Study
Ostropolets et al. (2021) studied this question.